Having trouble accessing articles? Reset your cache.

Cypress Bioscience, Ramius LLC deal

Cypress shareholder Ramius began an unsolicited tender offer to acquire the 90.1% of Cypress it does not already own for $4.25

Read the full 219 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE